Relmada Therapeutics (RLMD)
(Delayed Data from NSDQ)
$3.49 USD
+0.01 (0.29%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $3.54 +0.05 (1.43%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 11/13/24 |
---|---|
Current Quarter | -0.65 |
EPS Last Quarter | -0.59 |
Last EPS Surprise | 28.92% |
ABR | 2.20 |
Earnings ESP
|
-1.54% |
---|---|
Current Year | -2.50 |
Next Year | -2.32 |
EPS (TTM) | -2.88 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.65 | -0.54 | -2.50 | -2.32 |
# of Estimates | 2 | 2 | 2 | 2 |
Most Recent Consensus | -0.66 | NA | -2.45 | NA |
High Estimate | -0.64 | -0.48 | -2.45 | -1.30 |
Low Estimate | -0.66 | -0.60 | -2.54 | -3.33 |
Year ago EPS | -0.73 | -0.84 | -3.28 | -2.50 |
Year over Year Growth Est. | 10.96% | 35.71% | 23.78% | 7.20% |
Agreement - Estimate Revisions
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 0 | 1 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 1 | 0 | 1 | 0 |
Down Last 60 Days | 1 | 0 | 1 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.65 | -0.54 | -2.50 | -2.32 |
7 Days Ago | -0.65 | -0.54 | -2.50 | -2.32 |
30 Days Ago | -0.56 | -0.54 | -2.40 | -2.32 |
60 Days Ago | -0.56 | -0.54 | -2.40 | -2.38 |
90 Days Ago | -0.74 | -0.76 | -3.04 | -2.94 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.66 | -0.54 | -2.45 | -2.32 |
Zacks Consensus Estimate | -0.65 | -0.54 | -2.50 | -2.32 |
Earnings ESP | -1.54% | 0.00% | 1.80% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (6/2024) |
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.59 | -0.72 | -0.84 | -0.73 | NA |
Estimate | -0.83 | -0.90 | -0.88 | -0.95 | NA |
Difference | 0.24 | 0.18 | 0.04 | 0.22 | 0.17 |
Surprise | 28.92% | 20.00% | 4.55% | 23.16% | 19.16% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more